Key Points
- Insider sale: Glaukos director Gilbert Kliman sold 5,000 shares on May 14 at an average price of $140.76, totaling about $703,800. After the transaction, he still owned 35,528 shares.
- Company performance: Glaukos reported quarterly EPS of -$0.18, beating estimates, and revenue of $150.57 million, up 41.2% year over year and above analyst expectations.
- Wall Street outlook: Analysts remain generally positive, with a consensus rating of Moderate Buy and an average price target of $144.42, though one firm still rates the stock a sell.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the sale, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. This trade represents a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Glaukos Trading Down 1.1%
Glaukos stock opened at $142.43 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos Corporation has a one year low of $73.16 and a one year high of $148.11. The stock has a market capitalization of $8.37 billion, a PE ratio of -43.42 and a beta of 0.94. The business's fifty day moving average is $117.71 and its 200 day moving average is $112.10.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million for the quarter, compared to analysts' expectations of $137.00 million. During the same period last year, the firm posted ($0.22) earnings per share. Glaukos's revenue was up 41.2% compared to the same quarter last year. On average, sell-side analysts predict that Glaukos Corporation will post -0.57 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Alliance LLC boosted its stake in shares of Glaukos by 4.5% during the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier's stock worth $247,000 after acquiring an additional 98 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock worth $158,000 after acquiring an additional 122 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 132 shares during the last quarter. CWM LLC boosted its stake in shares of Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock worth $80,000 after acquiring an additional 143 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of Glaukos by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock valued at $947,000 after buying an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. Stifel Nicolaus set a $170.00 target price on shares of Glaukos in a report on Thursday, April 30th. Needham & Company LLC raised their target price on shares of Glaukos from $127.00 to $136.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a research report on Tuesday, April 21st. BTIG Research raised their target price on Glaukos from $131.00 to $141.00 and gave the stock a "buy" rating in a research report on Thursday, April 30th. Finally, William Blair raised Glaukos to a "strong-buy" rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and an average price target of $144.42.
Get Our Latest Report on GKOS
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
